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Abstract
Background: The role of extranodal extension (ENE) in penile cancer is controversial and has not been well
studied. The aim of this study was to investigate the importance of ENE in predicting prognosis and presence of
pelvic lymph node metastasis (PLNM) in penile cancer patients.
Methods: We searched related studies in Medline, Embase, Cochrane Library, and Scopus database. Hazard ratio
(HR) and odds ratio (OR) were directly extracted or indirectly estimated from the included studies.
Results: A total of ten studies with 1,142 patients were included in this meta-analysis. Patients with ENE showed a
worse cancer-specific survival (CSS) (HR = 1.90, 95 % confidence interval [CI] = 1.35–2.67, P = 0.0002) and overall
survival (HR = 4.04, 95 % CI = 1.02–16.1, P = 0.05) than those without ENE. Further subgroup analysis revealed that
the predictive value of ENE for CSS in penile cancer patients was significant regardless of the study’s country of
origin, but not in the subgroup with shorter follow-up time (<36 months, P = 0.38). Patients with ENE also showed a
higher incidence of presenting with PLNM (OR = 4.95, 95 % CI = 2.58–9.49, P < 0.001). A stratified analysis demonstrated
that the predictive role of ENE for PLNM was only detected in studies with a larger sample size (> 100 cases). No
significant publication bias was observed, as suggested by Begg’s and Egger’s tests.
Conclusions: ENE is associated with worse prognosis and high risk of PLNM in penile cancer patients. Due to the
limited number of studies included in this meta-analysis, a large-scale, well-designed study will be required to verify
our results.
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Background
Penile cancer is an uncommon malignancy, with an inci-
dence of less than 1/100,000 in Western countries [1, 2].
The prevalence of penile cancer is higher in developing
regions, yet the overall tendency is showing a decrease
in morbidity [3–5]. It is imperative to identify prognostic
factors of this disease, however due to its rarity this task
is difficult. Generally, the most widely accepted prognos-
tic factor of penile cancer is the status of the regional
lymph nodes [6–8]. The 7th American Joint Committee
on Cancer (AJCC) cancer staging manual [9] categorizes
patients with a single positive inguinal lymph node as
pN1, and multiple as pN2. Penile cancer with inguinal
lymph node metastasis (LNM) shows a poorer prognosis
than those without inguinal LNM. In addition, the prog-
nosis of patients with pelvic lymph nodes metastasis
(PLNM) is even worse [10–12].
Extranodal extension (ENE) is defined as extension of
tumor through the lymph node capsule into the perino-
dal fibrous-adipose tissue. Along with the number and
location of LNM, ENE is also considered a negative
prognostic factor in penile cancer patients. In the latest
AJCC TNM staging [9], both ENE and PLNM are staged
as pN3, suggesting that ENE is an extremely terrible
pathologic finding. However, the role of ENE in penile
cancer is still controversial. Certain studies have indi-
cated that penile cancer patients with ENE had a lower
5-year survival rate compared with those without ENE
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[13–16]. Several other reports, however, find that ENE is
not an independent prognostic factor [17, 18]. As for
PLNM, the European Association of Urology (EAU)
guideline recommends considering ENE in inguinal
lymph nodes as a risk factor for PLNM [19], even
though some studies have failed to find a significant
predictive role of ENE for PLNM [16, 20, 21]. The
above-mentioned contradictory results contribute to
the uncertainty of the role of ENE in penile cancer.
These controversial results regarding ENE may be at-
tributed to the rarity of penile cancer. Both the number
of patients and statistical power in each individual study
is limited. In the current study, we performed a meta-
analysis that pooled together all the related studies fo-
cusing on the role of ENE in penile cancer. We aimed to
better illuminate the importance of ENE in predicting
survival and the risk of PLNM in penile cancer patients.
Methods
This meta-analysis was preformed following the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) criteria [22].
Literature search strategy
We performed a search in the Medline, Embase,
Cochrane Library and Scopus databases to identify rele-
vant studies for this meta-analysis. Our search duration
lasted until November 18, 2014. We utilized the follow-
ing terms and combinations for searching: “penile cancer
or carcinoma of penis or penis cancer or penile neo-
plasms” and “extranodal or extra capsular or capsular
penentration or perinodal”. Furthermore, references of
retrieved articles and reviews were manually screened
for additional studies.
Inclusion and exclusion criteria
Studies were considered eligible if they met both of the
following criteria: (1) published in English and (2) re-
ported the association between ENE and prognosis and/
or the risk of PLNM of penile cancer. Studies were ex-
cluded based on the following criteria: (1) letters, case
reports, reviews, and conference abstracts; (2) studies
which did not provide sufficient information to estimate
hazard ratio (HR) or odds ratio (OR) and 95 % confi-
dence interval (CI); and (3) studies with duplicated data
or a repeated analysis. When the same group reported
duplicated data in papers, we only included the most in-
formative one.
Data extraction and quality assessment
We extracted the useful data from eligible studies by
using a standard information collection survey including
the following items: first author’s name, publication year,
recruitment period, country of origin, follow-up time,
number of patients, number of patients with ENE, and
HR/OR with 95 % CI. The quality of the included stud-
ies was assessed by the Newcastle-Ottawa Scale (NOS)
[23]. Studies with seven or more stars were defined as
high quality studies. Two authors (Zhi-Ling Zhang and
Chun-Ping Yu) independently reviewed the above data,
and all disparities were resolved by discussions between
the authors.
Statistical analysis
In order to analyze the impact of ENE on the survival of
penile cancer patients, we synthesized survival data from
the included studies using the reported HR and its 95 %
CI. When the survival data was not directly reported, we
used a mathematical estimation to calculate the neces-
sary data with the methods reported by Tierney et al.
[24]. By convention, an observed HR > 1 implied worse
survival for patients with ENE. The association between
ENE and PLNM was evaluated by OR. All numbers
needed for calculating OR and their 95 % CIs were dir-
ectly extracted from the multivariable logistic regression
or univariate analysis. If a study provided both, the re-
sults of multivariable and univariate analysis, we used
the former. We used Higgins I2statistic to quantify the
heterogeneity of the pooled results. If it was I2 < 50 %,
indicating the absence of heterogeneity, then a fixed-
effects model was used to estimate the pooled HRs/ORs.
Otherwise, the random-effects model was used. Sub-
group analysis was used to detect the potential hetero-
geneity among studies. Begg’s funnel plot and Egger’s
linear regression test were conducted to examine publi-
cation bias in the literature [25, 26]. A sensitivity analysis
was conducted to confirm the robustness of the pooled
results, during which data from each individual study
was sequentially removed. All P values were two-tailed
and the P values of <0.05 were considered statistically
significant. The statistical analysis was conducted using
STATA 11 (StataCorp, College Station, Texas, USA).
Results
Summary of analyzed studies
The present study met the PRISMA statement (Additional
file 1). In total, 65 studies were identified from an
initial search, and 3 studies were excluded for dupli-
cated reporting. All the 62 studies were screened and
48 studies were excluded by screening of titles and
abstracts. The remaining 14 original studies were then
reviewed by careful screening of the full texts, after
which 4 were eliminated due to lack of eligible data.
Finally, 10 studies were chosen to be included in this
meta-analysis (Fig. 1).
Table 1 summarized the main characteristics of the
included studies. A total of 1,142 patients were in-
cluded in this meta-analysis, ranging from 33 to 300
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in each individual study. Of the 10 eligible studies, 4
were carried out in Asian [14, 16, 21, 27], 4 in European
[13, 18, 20, 28], and 2 in North American [15, 17]
countries; 6 studies reported the association between
ENE and prognosis [13–15, 17, 18, 27], 3 studies in-
vestigated the relationship between ENE and PLNM
[20, 21, 28], and 1 study focused on both [16]. In the
7 studies that provided prognostic information [13–
18, 27], 4 used cancer specific survival (CSS) [13, 15,
17, 18], 2 used overall survival (OS) [14, 16], and only
1 used recurrence-free survival [27]; 5 listed HR and
its 95 % CI in multivariable Cox regression [13, 14,
17, 18], and 2 provided survival curves for calculating
them [15, 27]. ORs and 95 % CIs were directly ex-
tracted from 3 studies [16, 20, 28] and calculated in-
directly in 1 study [21]. The quality of the included
studies was evaluated, revealing that 9 (90 %) were
high quality and 1 (10 %) was moderate.
Association between ENE and survival in penile cancer
patients
Since there was only one study that used recurrence-
free survival to evaluate the prognosis, it was ex-
cluded from the prognostic analysis [27]. The overall
analysis revealed that patients with ENE had a worse
CSS compared to those without ENE (HR =1.90,
95 % CI = 1.35–2.67, P < 0.001) (Fig. 2a). Furthermore,
we performed a subgroup analysis looking at the
study’s country of origin and follow-up time. We
found a significant association between ENE and CSS
in both European (HR = 1.54, 95 % CI: 1.01–2.36) and
North American (HR = 2.79, 95 % CI: 1.58–4.92) co-
horts. Then, we subdivided studies based on follow-
up time. We found that the association between ENE
and CSS was only present in studies with a median
follow-up time longer than 36 months, but not in
those with shorter follow-up time (Table 2).
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow diagram
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Table 1 Main characteristics of the studies included in this meta-analysis










Outcomes measured NOS score
Djajadiningrat [13] 2014 Netherlands 1956–2012 retrospective 64 65 m 300 134(45) NA 58(19) CSS: Multivariable HR reported 8
Lughczznni (a) [18] 2013 Italy 2000–2012 retrospective 61 26 m 81 40(49) 56(69) NA CSS: Multivariable HR reported 8
Pandey [14] 2006 India 1987–1998 retrospective 45 NA 102 54(53) NA 21(22) OS: Multivariable HR reported 8
Svatek [17] 2009 USA 1979–2007 retrospective 61 24 m 45 11(24) 33(73) NA CSS: Multivariable HR reported 8
Sun [15] 2014 Canada 1994–2010 retrospective 65 43 m 155 71(46) NA 31(7.1) CSS: Curve estimated HR 7
Zhu(a) [27] 2011 China 1990–2008 retrospective 48 53 m 60 16(27) 29(48) 8(13) RFS: Curve estimated HR 7
Liu [16] 2013 China 1998–2011 retrospective 51 42 m 76 29(38) 42(55) 33(43) OS: Multivariable HR reported 6
PLNM: Multivariable OR reported
Zhu(b) [21] 2008 China 1990–200 retrospective NA 38 m 33a 5(15) 16(48) 12(36) PLNM:univariateOR calculated 7
Lont [20] 2007 Netherlands 1956–2011 retrospective 63 85 m 102 NA 53(52) 25(25) PLNM: Multivariable OR reported 8
Lughczznni (b) [28] 2014 Italy 1985–2012 retrospective 63 51 m 188b 98(52) 160(85) 51(27) PLNM: Multivariable OR reported 8
NA not available, ENE extranodal extension, CSS cancer specific survival, OS overall survival, RFS recurrence free survival, PLND pelvic lymph node dissection, PLNM pelvic lymph node metastasis, OR odds ratio, HR
hazard ratio, NOS Newcastle-Ottawa Scale











For OS, patients with ENE showed a lower OS rate
compared with those without ENE (HR = 4.04, 95 % CI:
1.02–16.1, P = 0.05) (Fig. 2b). Only two studies were in-
cluded in this analysis, therefore a stratified analysis was
not performed.
Association between ENE and PLNM in penile cancer
patients
Four studies investigated the relationship between ENE in
inguinal lymph nodes and the presence of PLNM. Our
meta-analysis revealed that patients with ENE had a
higher risk of presenting with PLNM (Fig. 3, OR = 4.95,
95 % CI: 2.58–9.49, P < 0.001) and significant heterogen-
eity was not found (I2 = 0 %, P = 0.508). Subgroup analysis
revealed that the predictive role of ENE for PLNM was
only observed in studies with a sample size larger than
100 (OR = 5.54, 95 % CI: 2.63–11.68, P < 0.001). We also
took into consideration what each study identified as its
study object. For example, some studies identified the pa-
tient as the object, whereas others used the individual
Fig. 2 Meta-analysis of the pooled HRs of CSS (a) and OS (b) for penile cancer patients with ENE. HR > 1 implied ENE was significantly associated
with worse prognosis. CSS, cancer specific survival; OS, overall survival; ENE, extranodal extension; CI, confidence interval
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groin basins of the patient as the object. Our analysis re-
vealed that pooled HR for the “one patient as a study ob-
ject” group was 2.82 (95 % CI = 0.99–7.98, P = 0.05), while,
the “one groin basin as a study object” group was 7.11
(95 % CI = 3.08–16.38, P < 0.001).
Publication bias
We used Begg’s funnel plot and Egger’s test to evaluate
the publication bias of all the relevant studies. As shown
in Fig. 4, the shape of the funnel plot was symmetrical
for the all comparisons, revealing that there was no
Table 2 Stratified analysis of pooled hazard ratios for penile cancer patients with ENE
Analysis No. of studies (No. of patients) HR/OR (95 % CI) P Value Model Heterogeneity
I2 (%) Phet
Whole group CSS 4(581) 1.90(1.35,2.67) 0.0002 Fixed 29 0.24
Subgroup1:
Location
European 2(381) 1.54 (1.01, 2.36) 0.05 Fixed 0 % 0.40
North American 2(200) 2.79 (1.58, 4.92) 0.0004 Fixed 0 % 0.36
Subgroup2:
Follow-up time
< 36 months 2(126) 1.37 (0.68, 2.76) 0.38 Fixed 0 % 0.45
≥ 36 months 2(455) 2.26 (1.18, 4.34) 0.01 Random 60 % 0.11
Whole group PLNM 4(353) 4.95 (2.58, 9.49) <0.00001 Fixed 0 0.51
Subgroup1:
Sample size
≥ 100 2(244) 5.54 (2.63, 11.68) <0.00001 Fixed 0 % 0.44
< 100 2(109) 3.43(0.90, 13.11) 0.07 Fixed 26 % 0.25
Subgroup2:
Identification of study object
Individual patient 2(178) 2.82 (0.99, 7.98) 0.05 Fixed 0 % 0.71
Groin basin 2(221) 7.11 (3.08, 16.38) <0.00001 Fixed 0 % 0.56
ENE extranodal extension, CSS cancer specific survival, PLNM pelvic lymph node metastasis, OR odds ratio, HR hazard ratio, CI confidence interval
Fig. 3 Forest plots of the OR for the association of ENE with PLNM of penile cancer patients. OR > 1 indicates that ENE was significantly
associated with high risk of PLNM. OR, odds ratio; ENE, extranodal extension; PLNM, pelvic lymph node metastasis; CI, confidence interval
Zhang et al. BMC Cancer  (2015) 15:815 Page 6 of 10
Fig. 4 Funnel plot for all studies included in this meta-analysis. a and b funnel plot assessing ENE and cancer specific survival and overall survival,
respectively; c funnel plot assessing ENE and pelvic lymph node metastasis in penile cancer patients. ENE, extranodal extension; SE, standard error
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obvious publication bias. For the relationship between
ENE and CSS, the p value of Begg’s test was 1.000 and
0.890 for Egger’s test. The p value of Begg’s test for ENE
and OS was 1.000, and the p value of Begg’s test was un-
available due to the limited number of studies. Similarly,
the statistical results did not show evidence of publica-
tion bias for PLNM (Begg’s test, P = 0.734; Egger’s test,
P = 0.951).
Sensitivity analysis
In order to evaluate the stability of our results, we per-
formed a sensitivity analysis by removing one study at a
time. The results of the sensitivity analysis were shown
in Table 3. The corresponding pooled HR/OR did not
significantly change after sequentially omitting each
study, demonstrating that our results were stable and
reliable.
Discussion
As early as 1987, Srinivas et al. [6] reported that lymph
node positive penile cancer with ENE was associated
with a higher mortality than penile cancer without ENE.
Subsequent studies reported a 5-year survival rate of
9 %–42 % [14, 29] in penile cancer patients with ENE,
comparable to those with PLNM [10, 16, 28, 29]. Hence,
in the latest AJCC cancer staging system, both ENE and
PLNM were listed as pN3 stage. Several studies indi-
cated that ENE was not only a predictor of poor survival
[13–16], but also a risk factor for PLNM [18]. However,
the reports on the role of ENE were not consistent, and
some studies failed to find an independent predictive
value of ENE in predicting prognosis or PLNM. For ex-
ample, Lughezzani et al. [28] used multivariable Cox re-
gression models to identify the independent predictive
factors of CSS in penile cancer. They found that patients
with ENE showed a worse CSS with a HR of 1.069 and
95 % CI: 0.416–2.750, while the difference in prognosis
was not statistically significant (P = 0.889). Similar results
were reported by Svateket al.[17]. Moreover, three stud-
ies that focused on the role of ENE in predicting PLNM
failed to find a significant association [16, 20, 21]. In
order to better illustrate the role of ENE in penile can-
cer, we performed the present meta-analysis. Our study
shows advantages compared to the individual studies,
which are limited by small sample size and insufficient
statistical power, thereby clarifying the importance of
ENE in penile cancer patients. The results of the present
study reveal that penile cancer patients with ENE have
worse CSS and OS, as well as higher risk of presenting
with PLNM, compared to those without ENE.
Since the patient characteristics were different in each
included study, we performed a stratified analysis based
on the location of the study to detect the role of ENE in
penile cancer. Our results showed that the predictive
role of ENE in CSS was observed in both, European and
North American subgroups. This may be partly ex-
plained by the same race of the two regions. Another
reason for this phenomenon may be attributed to the
similar treatment protocol in these two regions. We also
found that the association between ENE and CSS was
significant only in the studies that had a median follow-
up time of no less than 36 months. It is not difficult to
understand this finding of increased mortality with a
prolonged follow-up time.
A subgroup analysis looking at the association between
ENE and PLNM revealed that ENE was associated with
PLNM in studies with a sample size larger than 100.
This finding is consistent with the basic statistical
principle that statistical difference may be left
unrecognized in small sample studies. Our analysis also
reveals an interesting finding regarding the differences
in how the study object is defined. The subgroup ana-
lysis showed that studies using one groin basin as the
study object had a significant predictive value of ENE for
PLNM. However, the studies that utilized one patient as
a study object did not obtain a statistically significant
pooled OR. The pattern of regional lymph node metasta-
sis in penile cancer is unique. Primary tumor first metas-
tasizes to unilateral, bilateral or contralateral inguinal
lymph nodes, after which metastasis can extend to the
ipsilateral pelvic lymph nodes. No skip metastasis has
been observed [19]. According to this observation, it is
theoretically more reasonable to predict PLNM using
groin basins as the study object. Our results confirm this
speculation.
When investigating the relationship between ENE
and OS of penile cancer patients, we found great het-
erogeneity, with an I2 value of 74 %. We tried to find
the origin of this heterogeneity by carefully reading
all the 10 eligible studies. Even though the utilized
protocols for lymph node dissection in penile cancer
were variable, the basic protocol was similar in most
of the included studies. However, in the study by
Pandey et al. [14], the indication for lymph node
Table 3 Sensitivity Analysis for CSS and PLNM
Study omitted HR or OR (95 % CI) P Value
CSS Djajadiningrat [13] 2.16 (1.33, 3.51) 0.002
Lughczznni (a) [18] 2.08 (1.44, 2.99) <0.0001
Svatek [17] 1.91 (1.33, 2.74) 0.0004
Sun [15] 1.58 (1.07, 2.34) 0.002
PLNM Liu [16] 5.91 (2.87, 12.18) <0.00001
Zhu(b) [21] 4.66 (2.39, 9.08) <0.00001
Lont [20] 5.44 (2.62, 11.29) 0.01
Lughczznni (b) [28] 3.42 (1.28, 9.13) <0.00001
CSS cancer specific survival, PLNM pelvic lymph node metastasis, HR hazard
ratio, OR odds ratio, CI confidence interval
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dissection was extremely different from the others,
and may be the source of heterogeneity. Their study
used fine needle aspiration cytology (FNAC) to iden-
tify potential positive lymph nodes. Lymph node dis-
section was only conducted on FNAC positive
inguinal lymph nodes or on those with clinically obvi-
ous or suspiciously enlarged nodes after the primary
penile cancer surgery. As we know, the accuracy of
FNAC in diagnosing LNM is limited, having a low
specificity [8, 30]. Hence, the current EAU guideline
does not recommended FNAC as a method for sta-
ging [19]. In the study by Pandey et al. (14), some pa-
tients with a positive inguinal lymph node missed
synchronous lymph node dissection and only received
salvage lymph node dissection after the inguinal
lymph nodes became larger. This explains the high
percentage of ENE positive and PLNM patients in
their study [14].
Our study has some limitations. (1) The number of
included studies was small; the analysis of CSS and
PLNM each had only four eligible studies, and the
OS analysis included only two studies. As a conse-
quence, this limitation should be taken into consider-
ation when interpreting the results. A well-designed
study with a larger sample size will be needed to val-
idate our results. (2) Great heterogeneity existed in
the analysis for OS, but since only 2 studies were in-
cluded, no subgroup analysis was performed to iden-
tify the reason for the heterogeneity. (3) We
preferentially extracted HR from multivariable ana-
lysis, which was adjusted for other factors. However,
the adjusted factors were not the same in HRs that
were directly extracted from multivariate Cox analysis.
We used the Kaplan-Meier curves to estimate the
HRs in studies in that did not directly provide HRs.
All of these factors, more or less, contributed to the
observed heterogeneity. (4) We only searched the da-
tabases for studies in the English language, and
ignored non-English or unpublished studies. (5) Adju-
vant and/or neoadjuvant therapy might impact the
prognosis of penile cancer [31, 32]. However, we
failed to perform subgroup analysis on the percentage
of patients that received adjuvant and/or neoadjuvant
therapy due to the fact that not every included study
provided this data.
Conclusions
In summary, ENE is associated with worse CSS and OS
for penile cancer patients. Our data also shows that pa-
tients with ENE in inguinal lymph nodes have higher
risk of presenting with PLNM. However, because the
number of included studies is small, well-designed stud-
ies with a large sample size are needed to confirm our
results.
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